Lv7
4740 积分 2021-11-19 加入
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs
27天前
已完结
Covariate-Adjusted Difference in Proportions from Clinical Trials Using Logistic Regression and Weighted Risk Differences
1个月前
已完结
Statistical methods for handling missing data to align with treatment policy strategy
2个月前
已完结
Prognostic implications of the arginine metabolism in patients at nutritional risk: A secondary analysis of the randomized EFFORT trial
2个月前
已完结
Success and Futility Criteria for Accelerated Approval of Oncology Drugs
3个月前
已完结
Review of calculation of conditional power, predictive power and probability of success in clinical trials with continuous, binary and time-to-event endpoints
5个月前
已完结
Chasing Shadows: How Implausible Assumptions Skew Our Understanding of Causal Estimands
6个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
6个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
6个月前
已完结
皖公网安备34019202002308
